

May 03, 2018

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

The Bombay Stock Exchange Ltd
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001

Dear Sirs,

Sub: Presentation on Annual Results for the year ended 31-03-2018.

--0--

We are forwarding copy of Presentation on Annual Results of our company for the year ended 31-03-2018.

Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised.

Yours Faithfully,

For **Thyrocare Technologies Limited,**

Ramjee Dorai

Company Secretary and Compliance Officer



Thyrocare
Technologies
Limited

Q4-FY18 / FY18
Presentation

Thyrocare®

Think Thyroid. Think Thyrocare.

Nuclear™
NATIONWIDE NETWORKED

Disclaimer

- This presentation is for information purposes only and it contains general background information about the Company's activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, information or events, or otherwise. This Presentation comprises information given in summary form and does not purport to be complete. This Presentation should not be considered as a recommendation to any investor to purchase the equity shares of the Company. This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future financial condition and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. The past performance is not indicative of future results.*
- This document has not been and will not be reviewed or approved by the statutory auditors or a regulatory authority in India or by any stock exchange in India.*


FY18A and Q4-FY18 Highlights

Key Highlights* – FY2018


- FY18A Highlights:
 - FY2018 Consolidated Profit Before Exceptional Items & Tax Of ₹ 1,472 Million, ▲ 35%
 - FY2018 Consolidated EBITDA Of ₹ 1,443 Million, ▲ 26%
 - FY2018 Consolidated Revenues Of ₹ 3,563 Million, ▲ 17%
- Q4-FY18A Highlights:
 - Quarterly Consolidated Profit Before Exceptional Items & Tax Of ₹ 423 Million, ▲ 47%
 - Quarterly Consolidated EBITDA Of ₹ 371 Million, ▲ 18%
 - Quarterly Consolidated Revenue Of ₹ 967 Million, ▲ 11%

Pathology – Attractive CAGRS on all metrics


Pathology Revenues (INR mn)



Number of Samples (mn)




Number of Investigations (mn)




Imaging has consistently grown; 30%+ in FY18A

Imaging Revenues (INR mn)




Number of Scans



Group CAGR – 25% over 3 years

Consolidated Group Revenues (INR mn)



Transition to IndAS (Indian Accounting Standards)

[Rs. in million]

	Year ended 31 March 2017		Qtr ended 31 March 2017	
	Consolidated	Standalone	Consolidated	Standalone
Net profit (after tax) under Indian GAAP	709.64	748.46	189.50	203.05
Add/ (less) : Adjustment for GAAP differences				
Net gain arising on fair value accounting of financial assets/ liabilities (mutual fund, security deposit, etc.)	2.51	12.52	3.33	4.46
Accounting of employees stock options as per Black Scholes valuation model	0.20	0.20	(0.15)	(0.15)
Net actuarial gain on employee benefit plans reclassified to Other Comprehensive Income (OCI)	(0.52)	(0.50)	(0.27)	(0.26)
Others				
Adjustment on account of prior period transactions	(8.27)	(8.27)	(7.54)	(7.54)
Deferment of one time association fees	(0.59)	4.85	(0.01)	3.59
Recognition of contribution towards advertisement	(274.33)	(274.33)	(40.36)	(40.36)
Deferred tax on the above adjustments	(0.19)	(16.23)	9.54	(6.49)
Net profit before OCI/ reserve as per Ind AS	428.45	466.70	154.04	156.30
% change in the net profit on transition to IndAS	-40%	-38%	-19%	-23%

Key IndAS Adjustments:

- Re-imburement of advertisement expenses by shareholders – Non reciprocal contributions received from the shareholders are considered as capital contribution and the expenses incurred thereof considering the nature and size are recognized as exceptional expenses.
- Sale of product with sale of services under linked transaction are recognized as single transaction therefore clubbed together. The incentive paid to service provider is adjusted against revenue. The fees collected from service provider at inception is amortised over a period of association.
- As an accounting policy choice adopted, the carrying value of property plant and equipment and the investment in subsidiaries is deemed as the fair value on IndAS transition.
- The trademarks assigned to the Company and Subsidiary are recognised at fair value on the basis of valuation certificate. The value of goodwill is tested for impairment.
- The consideration paid to the manufacturers/ vendors under contractual arrangement for purchase of reagents is bifurcated into lease rental and reagent purchase cost on the estimates basis on the terms of placement of these analysers.
- The accounts of ESOP trust are consolidated with the company as the controls are exercised on the related activities by the entity.
- The ESOP liabilities have been determined on fair value of options under the Black and Scholes model. The actuarial gain/ loss on employee benefit valuations adjusted through 'OCI'.
- Fair valuation of financial instruments such as interest-free security deposits, investments in mutual funds, long-term advances, etc.
- Deferred tax on GAAP adjustments.

Beginning 1 April 2017, the Company has for the first time adopted Indian Accounting Standards (Ind AS) with a transition date of 1 April 2016. Accordingly, the unaudited standalone financial results have been prepared in compliance with IndAS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India

Consolidated Financials

Consolidated Financials

Thyrocare Technologies Limited [Consolidated] P&L Statement (INR mn, except per share data)

Particulars	Financial Year Ending		YoY Growth	3 months ended		YoY Growth
	31 Mar 18	31 Mar 17		31 Mar 18	31 Mar 17	
Revenue from operations	3,563.15	3,043.87	17%	966.55	871.16	11%
Cost of Materials consumed/ sales	949.73	814.23	17%	259.82	236.53	10%
Gross margins	2,613.42	2,229.64	17%	706.73	634.63	11%
Operating expenses :						
Employee benefits expense	353.39	320.00	10%	113.08	96.86	17%
Finance cost	4.35	2.68		1.49	1.00	
Depreciation and amortisation expense	201.00	180.51	11%	56.01	49.30	14%
Other expenses	812.77	757.80	7%	221.54	221.66	0%
Total operating expenses	1,371.51	1,260.99	9%	392.12	368.82	6%
Operating profit	1,241.91	968.65	28%	314.62	265.81	18%
Other income, net	229.96	122.42	88%	108.82	21.62	403%
Exceptional items	(21.93)	(274.33)		-	(40.36)	
Profit before taxes	1,449.94	816.74		423.43	247.07	
Income tax and deferred tax	(517.19)	(388.29)		(172.13)	(93.03)	85%
Net profit	932.75	428.45		251.31	154.04	
Earnings per equity share						
Basic	17.39	7.99		4.68	2.90	
Diluted	17.34	8.13		4.66	3.02	

Thyrocare Technologies Limited [Consolidated] Balance Sheet (INR mn)

Particulars	31 Mar 18	31 Mar 17
Cash and cash equivalents	118.56	117.93
Current investments	1,000.98	1,041.59
Trade receivables	98.40	62.75
Property, plant and equipments	1,901.77	1,511.67
Non-current investments	-	-
Other assets	1,670.15	1,644.36
Total assets	4,789.86	4,378.29
Total liabilities	356.96	300.21
Total equity	4,432.90	4,078.08
Total liabilities and equity	4,789.86	4,378.29

Other income of INR 108.82 mn in 4QFY18 includes one time gains of INR 78.85 mn from the divestment of the "Whaters" business line.

Thyrocare Standalone

Standalone Financials

Thyrocare Technologies Limited

[Diagnostic business]

Particulars	Financial Year Ending		YoY Growth	(Rs. in million, except per share data)		YoY Growth
	31 Mar 18	31 Mar 17		3 months ended	31 Mar 17	
	Revenue from operations	3,317.94	2,975.27	16%	900.32	823.62
Cost of Materials consumed/ sales	908.44	779.47	17%	249.79	227.16	10%
Gross margins	2,409.50	2,195.80	16%	650.53	596.46	9%
Operating expenses :						
Employee benefits expense	324.89	302.21	8%	104.49	91.26	14%
Finance cost	4.02	2.57		1.16	0.89	
Depreciation and amortisation expense	120.83	116.91	3%	33.18	31.33	6%
Other expenses	694.53	746.41	8%	191.95	192.81	0%
Total operating expenses	1,144.27	1,168.10	8%	330.78	316.29	5%
Operating profit	1,265.23	1,027.70	24%	319.75	280.17	14%
Other income, net	236.34	114.08		115.52	21.94	
Exceptional items	(21.93)	(274.33)		-	(40.36)	
Profit before taxes	1,479.64	867.45		435.27	261.75	
Income tax and deferred tax	(519.26)	(400.75)		(158.63)	(105.45)	
Net profit	960.38	466.70		276.64	156.30	
Other comprehensive income (net of tax)	1.70	0.33		0.27	0.17	
Earnings per equity share						
Basic	17.91	8.69		5.15	2.91	
Diluted	17.85	8.69		5.12	2.91	

Thyrocare Technologies Limited

Balance sheet data


Particulars	31 Mar 18	31 Mar 17
Cash and cash equivalents	92.76	87.10
Current investments	1,000.98	1,041.59
Trade receivables	92.13	59.78
Property, plant and equipments	1,012.96	872.35
Non-current investments	1,946.74	1,946.74
Other assets	708.04	433.84
Total assets	4,853.60	4,441.40
Total liabilities	314.82	261.61
Total equity	4,538.78	4,179.79
Total liabilities and equity	4,853.60	4,441.40

Normalized for the adjustment of revenue/ cost of imaging business in the comparable previous period.


Other income of INR 108.82 mn in 4QFY18 includes one time gains of INR 78.85 mn from the divestment of the "Whaters" business line.

Key Financial Trends - Thyrocare


Revenue (INR mn)



EBITDA (INR mn)



EBITDA Margin(%)




Previous period figures are normalized for the adjustment of revenue/cost of imaging business.


* Q4-FY18 EBITDA is understated by INR 15mn on account of CSR spending. Normalized for this, the EBITDA margin for 4Q-FY18 will come to ~42%

Key Operating Metrics – Business Lines

Revenue Breakup (INR mn)




Volume Breakup ('000 Samples)




Key Operating Metrics – Regional Breakup

Value Breakup (INR mn)



Volume Breakup (mn Samples)



Operating Data

Thyrocare Technologies Limited

(Rs. in million, except per share data)

Particulars	Financial Year Ending		YoY Growth	3 months ended		YoY Growth
	31 Mar 18	31 Mar 17		31 Mar 18	31 Mar 17	
	B2B revenue (in million)	2,375.54		2,005.61	18%	
B2C revenue (in million)	707.28	626.65	13%	173.00	205.05	-16%
B2B revenue/ total revenue (%)	71.6%	70.1%	-	73.4%	67.4%	-
B2C revenue/ total revenue (%)	21.3%	21.9%	-	19.2%	24.9%	-23%
Preventivecare revenue (in million)	1,568.97	1,364.63	15%	409.59	427.94	-4%
Preventivecare revenue/ Revenue from	47.3%	47.7%	-	45.5%	52.0%	-
Preventivecare revenue from B2B segment (%)	39.0%	40.2%	-	38.1%	43.7%	-
Preventivecare revenue from B2C segment (%)	90.8%	89.1%	-	91.1%	90.4%	-
Revenue - East/ revenue (%)	17.4%	17.3%	-	17.7%	17.3%	-
Revenue - West/ revenue (%)	30.5%	29.7%	-	29.7%	31.2%	-
Revenue - South/ revenue (%)	25.9%	28.1%	-	26.2%	26.3%	-
Revenue - North/ revenue (%)	24.4%	24.4%	-	22.8%	24.7%	-
Revenue - others/ revenue (%)	1.8%	0.6%	-	3.5%	0.5%	-
Gross margins/ total revenue (%)	72.6%	72.7%	-	72.3%	72.4%	-
Employee benefits expense/ total revenue (%)	9.8%	10.6%	-	11.6%	11.1%	-
Other expenses/ total revenue (%)	20.9%	22.4%	-	21.3%	23.4%	-
EBITDA margins/ total revenue (%)	41.8%	39.6%	5%	39.2%	37.8%	4%
Profit after tax / total revenue (%)	28.9%	15.7%	-	30.7%	19.0%	-
Effective tax rate - Tax/ PBT	35.1%		-	36.4%		-

previous period revenue, expenses and profits adjusted for internal arrangements

Nuclear Standalone

Standalone Financials - Nueclear

Nueclear Healthcare Limited

[Radiology business]

(Rs. in million, except per share data)

Particulars	Financial Year Ending		YoY Growth	3 months ended		YoY Growth
	31 Mar 18	31 Mar 17		31 Mar 18	31 Mar 17	
	Revenue from operations	245.21	173.10	33%	66.23	47.54
Cost of Materials consumed/ sales	42.27	34.75	22%	10.03	9.38	7%
Gross margins	202.94	138.35	36%	56.20	38.16	47%
Operating expenses :						
Employee benefits expense	28.18	17.79	58%	8.59	5.60	53%
Finance cost	9.22	0.29	0%	5.44	-	0%
Depreciation and amortisation expense	80.17	63.61	26%	22.83	17.97	27%
Other expenses	125.45	123.07	2%	31.97	30.80	4%
Total operating expenses	243.02	204.76	19%	68.83	54.37	27%
Operating loss	(40.08)	(66.41)	-28%	(12.63)	(16.21)	-22%
Other income, net	10.39	17.39		0.79	1.52	
Exceptional items	-	-		-	-	
(Loss) before taxes	(29.69)	(49.02)		(11.84)	(14.69)	
Income tax and deferred tax	2.26	16.51	-	(13.32)	-	-
Net profit	(27.43)	(32.51)		(25.16)	(14.69)	
Earnings per equity share						
Basic	(2.47)	(2.93)		(2.26)	(1.32)	
Diluted	(2.47)	(2.93)		(2.26)	(1.32)	

Nueclear Healthcare Limited


Balance sheet data

Particulars	31 Mar 18	31 Mar 17
Cash and cash equivalents	25.79	9.68
Current investments	-	-
Trade receivables	6.27	2.97
Property, plant and equipments	871.86	621.53
Non-current investments	-	-
Other assets	184.47	302.58
Total assets	1,088.39	936.76
Total liabilities	299.00	135.04
Total equity	789.39	801.72
Total liabilities and equity	1,088.39	936.76


Normalized for the adjustment of revenue of imaging business in the comparable previous period.

Key Financial Trends - Nueclear


Revenue (INR mn)




EBITDA (INR mn)




EBITDA Margin



Centerwise Scan Volumes



Centerwise Scan Revenues



Thank You

Thyrocare[®]

Think Thyroid. Think Thyrocare.

Nu^eclear[™]

NATIONWIDE NETWORKED